Evaluation of the effect of Ivermectin in treatment of patients admitted with COVID-19

Phase 3

Recruiting

• Conditions: COVID-19 infection.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20111224008507N5
• Lead Sponsor: Mazandaran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 April 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

Patients with positive coronavirus rapid test or RT-PCR
Age>5 years
Weight >15 kg
No treatment with antiviral drugs before and during the study
Informed consent for participation

Exclusion Criteria

Underlying liver and kidney disease
Patients with acquired immunodeficiency
Pregnancy and lactation

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduction in persistent cough. Timepoint: Daily until improvement. Method of measurement: Question from the patient.;Negative RT-PCR result. Timepoint: 6 days after the intervention. Method of measurement: RT-PCR.;The main complaints recovery time. Timepoint: Daily until symptoms resolve. Method of measurement: Checklist containing patient complaints.;Mortality. Timepoint: Daily. Method of measurement: Record in checklist.;Drug side effect (Wheezing, itching, skin rash, edema, and hypotension). Timepoint: Daily. Method of measurement: Question from the patient.;Reduction in tachypnea. Timepoint: Daily. Method of measurement: Medical record.;Oxigen saturation >94%. Timepoint: Daily. Method of measurement: Medical record.